This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through November 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
4 Commercial-Stage Biotechs Poised for Sustained Revenue Growth
by Ahan Chakraborty
TGTX, BCRX, INSM and MDGL are expanding product sales through rising demand, broader patient access and new market opportunities.
BCRXPositive Net Change INSMPositive Net Change TGTXPositive Net Change MDGLPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Moderna's First Cancer Therapy Win FDA Approval in 2027?
by Sundeep Ganoria
MRNA targets a year-end 2026 FDA filing for its personalized cancer therapy, intismeran, potentially paving the way for a regulatory decision in 2027.
MRNANegative Net Change SNYPositive Net Change PFEPositive Net Change MRKNegative Net Change
biotechs medical messenger-rna pharmaceuticals utilities
Novo Up 4% in a Month: How Should Investors Approach the Stock Now?
by Ahan Chakraborty
NVO gains 4% in a month on strong Q3 Wegovy pill sales and raised guidance, but intensifying competition and pricing pressures cloud its growth outlook.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will Bristol Myers' Growth Brands Offset Eliquis Headwinds?
by Ekta Bagri
Bristol Myers' Growth Portfolio drives 57% of revenues, with key brands gaining traction to offset legacy drug declines and support growth.
BMYPositive Net Change PFEPositive Net Change MRKNegative Net Change
biotechnology biotechs pharmaceuticals
Moderna (MRNA) Stock Hits 52-Week Highs After Q3 Earnings: Buy, Hold, or Sell?
by Shaun Pruitt
Moderna stock has surged as much as 10% in Friday's trading session, reaching a fresh 52-week high after delivering much stronger-than-expected Q3 results.
MRNANegative Net Change MRKNegative Net Change LLYPositive Net Change ABBVPositive Net Change
biotechnology biotechs earnings genetics investing large-cap medical pharmaceuticals
MRNA Q3 Earnings Beat on COVID Sales, Raises '26 Outlook, Stock Rises
by Zacks Equity Research
Moderna's Q3 earnings beat estimates on strong COVID-19 vaccine sales, returning to profitability and boosting its 2026 revenue growth outlook.
MRNANegative Net Change MRKNegative Net Change ABUSPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Halozyme Stock Down Despite Q3 Earnings and Revenue Beat
by Zacks Equity Research
HALO's Q3 earnings & revenues beat estimates, driven by higher royalties and product sales. The company raises its 2026 outlook, yet shares fall in after-hours.
HALONegative Net Change RHHBYNegative Net Change JNJNegative Net Change ARGXPositive Net Change
biotechs earnings
SRPT Q3 Earnings Miss Estimates, Stock Down as Elevidys Sales Decline
by Zacks Equity Research
Sarepta's mixed Q3 results send shares down, as earnings miss and weaker Elevidys sales weigh on investor sentiment.
SRPTPositive Net Change RHHBYNegative Net Change AMRXPositive Net Change IBRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
HALO Q3 Earnings Call Highlights Royalty Growth and Patent Dispute
by Zacks Equity Research
Halozyme lifts its 2026 outlook after a 44% royalty surge, as ENHANZE expansion, Hypercon trials and a Merck patent dispute draw investors' focus.
HALONegative Net Change
biotechs earnings
NVAX Stock Falls 8% Despite Q3 Earnings & Sales Beat, Costs Decline
by Zacks Equity Research
Novavax shares fall 8% despite Q3 earnings and revenue beat as costs decline, while a Sanofi milestone drives a sharp increase in its 2026 outlook.
NVAXNegative Net Change SNYPositive Net Change PFEPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals